A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer
This research study is studying a combination of two targeted therapies as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
The drugs involved in this study are:
- Osimertinib (Tagrisso)
A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naive advanced EGFR mutant lung cancer
- ClinicalTrials.gov Identifier: NCT03392246
- Protocol Number: 17-540
- Principal Investigator: Daniel Costa
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required